Sign in
Taking people in United StatesPhase 2

Mother-donated immune cells added to antiviral medicine for newborns with congenital CMV disease

Tests adding maternal CMV-fighting T cells to antiviral treatment in newborns with CMV disease.

Key facts

Who runs it
New York Medical College
Where
Columbus, Los Angeles, St Louis, and Vallhala, United StatesSee the 4 sites
Trial code
Registry title
CMV CTLs in Neonates With CMV Infection
Status
Recruiting
Phase
Phase 2
People taking part
23 people, planned
Started
1 Jul 2023
Expected to end
31 Oct 2028
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CMV Cytotoxic T-Lymphocytes
  • Anti-viral Therapy
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for newborns up to 21 days old with moderate or severe CMV infection present from birth. The mother must be able to donate immune cells that react to CMV.

Age
21 days of life or younger
Sex
All
Disease stage
Moderate or severe congenital CMV disease, with at least one sign such as low platelets (≤ 50,000 mm3), enlarged liver or spleen, small head, brain changes, eye inflammation (chorioretinitis), severe hearing loss, or CMV in the brain fluid. Birth weight ≥ 2500 gms (> 1500 gms for babies small for gestational age). Gestational age ≥ 34 weeks. Blood counts and kidney and liver tests must meet set limits.
Biomarker or test result
CMV found by RT-PCR in urine, saliva, CSF or plasma, and/or a positive urine culture for CMV. The mother's T cells must react to CMV MACS® PepTivators, with IFN-gamma+ T cells > 0.01%.

Main reasons for not taking part

  • Baby receiving steroids (> 0.5 mg/kg prednisone equivalent) on the day of the CMV CTL infusion
  • Taking part in another experimental trial treating newborn CMV
  • Mother with a known history of HIV infection
  • Any medical condition the investigator thinks could affect taking part
  • Parent or legal representative unable or unwilling to follow the protocol or give consent

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age: ≤ 21 days of life
  • Birth Weight: ≥ 2500 gms. . For babies with intrauterine growth retardation (IUGR) (small for gestational age [SGA]) > 1500 gms
  • Gestational age: ≥ 34 weeks of age
  • Diagnosis of CMV viremia, viruria, and/or infection:Either one or more:; Elevated CMV by RT-PCR in urine, saliva, CSF, or plasma; and/or Positive urine culture for CMV
  • Moderate or Severe CMV Disease; Any one or more of the following attributable to congenital CMV infection:
  • Thrombocytopenia (≤ 50,000 mm3)
  • Multiple petechiae
  • Hepatomegaly
  • Splenomegaly
  • Intrauterine growth retardation
  • Increased transaminases
  • Increased bilirubin
  • Microcephaly
  • Ventriculomegaly
  • Intracerebral calcifications
  • Periventricular echogenicity
  • Cortical or cerebral malformation
  • Chorioretinitis
  • Severe neonatal hearing loss
  • CMV DNA by PCR in CNS
  • Increased WBC for age in CNS; Minimal Organ Criteria Hematological: ANC ≥ 750/mm3, HgB ≥ 8gm/dl, Platelets ≥ 20,000/kmm3 Renal: Serum creatinine ≤ 1.0 mg/dl Hepatic: ALT/SGOT ≤3x upper normal limits; Donor Availability: Maternal donor available with a T-cell response CMV MACS® PepTivators. the donor is considered suitable if the percentage of IFN-gamma+ T cells is > 0.01% after stimulation with PepTivators

Who cannot take part

  • Patient receiving steroids (> 0.5 mg/kg prednisone equivalent) on the same day of CMV CTL infusion. Antenatal steroids for lung maturation will have been cleared prior to CMV diagnosis
  • Concomitant enrollment in another experimental clinical trial investigating the treatment of neonatal CMV viremia and/or infection
  • Any medical condition that could compromise participation in the study according to the investigator's assessment
  • Known history of HIV infection in the mother
  • Patient's legally authorized representative unwilling or unable to comply with the protocol or unable to give informed consent

Where in United States

  • Nationwide Children's HosptialColumbus, United StatesContact: Masako Shimamura, MDTaking people
  • Children's Hospital Los AngelesLos Angeles, United StatesContact: Ashley Gray, MDTaking people
  • Washington UniversitySt Louis, United StatesContact: Carol Kao, MDTaking people
  • New York Medical CollegeVallhala, United StatesContact: Mitchell Cairo, MDTaking people

About the trial

What the trial wants to find out

Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened.

Read full original descriptionShow less

All patients will receive treatment with valganciclovir or ganciclovir. There is a safety run in with treatment with CMV CTLs in cohort 1 and if found to be safe, will proceed to cohort 2 for randomization to receive antiviral therapy with or without CMV CTLs. There is a cross-over design for patient assigned to SOC only if they have persistent disease.

Funding source: FDA OOPD

The 4 groups in the trial

  • Cohort 1 Safety Run-inTreatment being tested

    The first 3 patients enrolled will receive both anti-viral medication and CMV CTLs, and treatment will be staggered every 28 days from the last dose of CMV CTLs from the prior patient.

    Treatment: CMV Cytotoxic T-Lymphocytes and Anti-viral Therapy

  • Cohort 2 Antiviral medication + CMV CTLsTreatment being tested

    Patients will receive both anti-viral medication and CMV CTLs

    Treatment: CMV Cytotoxic T-Lymphocytes and Anti-viral Therapy

  • Cohort 2 Antiviral medication onlyExisting treatment, for comparison

    Patients will only receive anti-viral therapy

    Treatment: Anti-viral Therapy

  • Cross-OverTreatment being tested

    Patients assigned to the SOC may be eligible to cross-over to the CVM CTL treatment if they are not responding to SOC treatment with continued elevated CMV levels.

    Treatment: CMV Cytotoxic T-Lymphocytes and Anti-viral Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase II Open-Label Randomized Study of Anti-Viral Antibiotic Therapy With and Without Familial (Maternal) Cytomegalovirus (CMV) Cytotoxic T Lymphocytes (CTLs) in Neonates With Moderate/Severe Maternal Acquired CMV Infection
Plain-language title
Mother-donated immune cells added to antiviral medicine for newborns with congenital CMV diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
28 October 2026